Fourth, our study has preliminarily revealed through Western blotting analyses that the FXR/FGF15 and PI3K/AKT pathways may serve as potential mechanisms underlying the therapeutic effect of EC against T2DM. This evidence concerns the gene AKT1 and type 2 diabetes mellitus.